Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Whitney F. Handy; Keith T. Schmidt; Douglas K. Price; William D. Figg

doi:10.1080/15384047.2020.1796195

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Whitney F. Handy, Keith T. Schmidt, Douglas K. Price, William D. Figg^*

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Article › peer-review

Abstract

The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.

Original language	English
Pages (from-to)	782-784
Number of pages	3
Journal	Cancer Biology and Therapy
Volume	21
Issue number	9
DOIs	https://doi.org/10.1080/15384047.2020.1796195
State	Published - 1 Sep 2020

Keywords

ADT
CRPC
HSD3B1
docetaxel
germline mutations

Access to Document

10.1080/15384047.2020.1796195

Cite this

@article{4b2b1fa9f3a24aeb84f754c2a0f5feda,

title = "Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT",

abstract = "The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.",

keywords = "ADT, CRPC, HSD3B1, docetaxel, germline mutations",

author = "Handy, {Whitney F.} and Schmidt, {Keith T.} and Price, {Douglas K.} and Figg, {William D.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2020",

month = sep,

day = "1",

doi = "10.1080/15384047.2020.1796195",

language = "English",

volume = "21",

pages = "782--784",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

TY - JOUR

T1 - Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

AU - Handy, Whitney F.

AU - Schmidt, Keith T.

AU - Price, Douglas K.

AU - Figg, William D.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.

AB - The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.

KW - ADT

KW - CRPC

KW - HSD3B1

KW - docetaxel

KW - germline mutations

UR - http://www.scopus.com/inward/record.url?scp=85089500243&partnerID=8YFLogxK

U2 - 10.1080/15384047.2020.1796195

DO - 10.1080/15384047.2020.1796195

M3 - Article

C2 - 32791030

AN - SCOPUS:85089500243

SN - 1538-4047

VL - 21

SP - 782

EP - 784

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 9

ER -

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

Abstract

Keywords

Access to Document

Fingerprint

Cite this